468PA phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours

ConclusionsThis study is continuing to enroll pts and will identify the recommended dose of ADCT-601. Updated results, including pharmacokinetic data, will be presented at the meeting.Clinical trial identificationNIH (https://clinicaltrials.gov/ct2/show/NCT03700294) October 9, 2018.Editorial acknowledgementEditorial support was provided by Sindhu Doppalapudi and Becky Salisbury at Fishawack Communications Ltd, funded by ADC Therapeutics Ltd.Legal entity responsible for the studyADC Therapeutics.FundingADC Therapeutics.DisclosureA.W. Tolcher: Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Research grant / Funding (institution): ADC Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Adagene; Advisory / Consultancy: Agenus; Advisory / Consultancy: AroBioTX; Advisory / Consultancy, Research grant / Funding (institution): Ascentage; Advisory / Consultancy: Aximmune; Advisory / Consultancy: Bayer; Advisory / Consultancy: BioInvent; Advisory / Consultancy, Research grant / Funding (institution): Birdie; Advisory / Consultancy: Boston Bio; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Forbius; Advisory / Consultancy: HBM Partners; Advisory / Consultancy: Ignyta; Advisory / Consultancy: Immunome; Advisory / Consultancy: Immunomet; Advisory / Consultancy: Jazz; Advisory / Consultancy: Mekanistic; Advisory / Consultancy: Nanobiotix; Advisory / Consultancy: NBE Therapeutics; Advisory / Consultancy: ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research